Mckesson stock hits all-time high at 1030.5 USD

McKesson shares reached an all-time high of $1,030.50, up 21.93% over the past year and 24% over six months. In fiscal Q1 2027, adjusted EPS of $9.93 beat the $9.64 estimate and revenue of $105.38 billion beat the $103.82 billion estimate; the company also raised its full-year earnings outlook. McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion, while Wells Fargo raised its price target to $933 from $812 and maintained an Equal Weight rating.

Analysis

The earnings beat and guidance increase support near-term estimates, but the six-month rerating and new high raise the bar for further upside: incremental gains now depend more on continued estimate revisions than on the reported beat itself. The Wells Fargo target of $933 is notably below the quoted share price despite its estimate increases and Equal Weight stance—one analyst view, not a consensus valuation, but a useful signal that near-term expectations may have outrun at least some models. Treat the InvestingPro “undervalued” label cautiously absent its methodology and assumptions.

Over 1–3 months, the key test is whether subsequent guidance and results sustain the higher earnings trajectory. The Precision Medicine Group deal may broaden McKesson’s service mix, but purchase economics, integration costs, and contribution to earnings are not supplied; do not capitalize strategic rationale as realized value. Over 6–18 months, execution could strengthen differentiation versus Cardinal Health and Cencora, while failed integration or weaker-than-expected returns would make the acquisition a drag rather than a diversification benefit. The contrarian risk is that a defensive distribution business is being priced for continued execution just as the bar rises. No independent valuation or acquisition-return data here supports a fresh outright short.

Key Decisions for Investors

• Avoid chasing MCK after the run-up; for existing exposure, consider trimming into strength or maintaining a defined-risk hedge rather than adding solely on the earnings beat. Reassess after the next report for sustained guidance and estimate revisions.
• Set an acquisition watchlist: verify deal financing, closing timing, integration costs, and disclosed earnings contribution before assigning value to the Precision Medicine Group transaction. A delayed close or weak contribution would weaken the diversification thesis.
• Use Cardinal Health and Cencora as relative-performance checks, not an automatic pair trade. Consider a relative-value position only after comparing current valuation, growth expectations, and segment exposure; those data are absent here.
• Falsifiers for the cautious entry stance: further upward guidance revisions and evidence of acquisition returns could justify renewed upside participation; guidance cuts, integration slippage, or a sustained reversal of post-results estimate revisions would support reducing exposure.